Chuangxin International Secures RMB 100 Million Pre-B Financing to Continue Leading the Organoid Sector

VCBeat has learned at the earliest opportunity that,Recently, ACCURATE BIOTECHNOLOGY announced the completion of its Pre-B financing round of RMB 100 million.Amidst the rampant pandemic and a capital winter, ACCURATE BIOTECHNOLOGY secured hundreds of millions in financing within just two years, further solidifying its position as the leader in the organoid sector!This round of financing was led by Fortune Capital, with Guangzhou Financial Holdings Group, Guangzhou Development District Fund, Wanlian Securities, and Zhonghe Anke participating as co-investors. Existing investors, including Qudao Assets, continued to increase their investments.

Dr. Huang Min, Founder of the Companystated that this round of financing reflects investors' strong confidence in the industry and the company's development. ACCURATE BIOTECHNOLOGY will continue to increase its investment in the research and development of core technologies and products, as well as in talent acquisition,Building a Full-Lifecycle Technology Platform for Organoids, driving breakthroughs and upgrades in core technologies, and focusing on building a product portfolio and industrial chain layout encompassing organoid biomaterials, organoid-on-a-chip platforms, and artificial intelligence systems. Meanwhile, ACCURATE BIOTECHNOLOGY will continue to deepen its efforts in commercial translation and market expansion, providing standardized solutions for clinical patients in the field of precision therapy. In the realm of new drug development, ACCURATE BIOTECHNOLOGY is committed to addressing unmet market needs, enabling leapfrog advancements in drug discovery. Centered around the revolutionary technology of organoids, ACCURATE BIOTECHNOLOGY will accelerate its strategic layout, continuing to lead technological development and commercial translation in the organoid sector!

Fortune CapitalIt was stated that organoid technology holds broad application prospects and commercial potential in areas such as clinical medication guidance and new drug development. ACCURATE BIOTECHNOLOGY has accumulated profound technical expertise and data resources in this field, establishing a globally leading organoid technology platform. It has been recognized as the Guangdong Provincial Engineering Research Center for Organoid Technology and participated in the release of the world’s first expert consensus on the clinical application of organoids. Furthermore, its founding team is outstanding, complementary, and highly executable, with a clear strategic plan for future development. This marks Fortune Capital’s first investment in the organoid sector, and it is committed to working hand in hand with the company for mutual growth. We look forward to collaborating with ACCURATE BIOTECHNOLOGY to drive breakthroughs in organoid technology and product upgrades, bringing significant benefits to cancer patients worldwide!

Guangzhou Financial Holdings FundIt was stated that Guangzhou Financial Holdings Fund places great emphasis on investment and strategic layout in the biomedical sector, particularly in niche areas such as in vitro diagnostics (IVD). Currently, Guangzhou Financial Holdings Group serves as the actual controller of Da An Gene. Guangzhou Financial Holdings Fund has also made key investments in high-quality IVD projects, including Kangliming, which have grown into leading enterprises in their respective sub-sectors. ACCURATE BIOTECHNOLOGY represents another significant strategic move by Guangzhou Financial Holdings Fund in the field of precision medicine. As organoid-based drug sensitivity screening becomes increasingly mature in precision medicine applications, ACCURATE BIOTECHNOLOGY, as the most advanced enterprise in the organoid sector in terms of technology, distribution channels, and regulatory approvals, is well-positioned to fully capitalize on industry growth opportunities and emerge as another leading player in precision medicine. We look forward to strengthening cooperation and interaction between both parties to accelerate the clinical translation of organoid technology for the benefit of society.

Guangzhou Development District FundIt was stated that organoid technology, a cutting-edge innovation in life sciences that has seen rapid development in recent years, holds immense commercial potential in both clinical applications and drug development. As one of the earliest entrants into this field, ACCURATE BIOTECHNOLOGY stands out as a leading high-tech enterprise nurtured in Guangzhou’s fertile ground for entrepreneurship. As a local investment institution, the Guangzhou Development District Fund will spare no effort in supporting enterprises like ACCURATE BIOTECHNOLOGY to continuously expand and strengthen, working together to uphold Guangzhou’s status and reputation as an international hub for biopharmaceutical science and technology R&D.

Wanlian Tianze, the private equity fund subsidiary of Wanlian Securities, and Wanlian Guangsheng, its investment subsidiarystated, “We are delighted to participate in this round of financing for ACCURATE BIOTECHNOLOGY. As an innovative biomedical company centered on organoid technology, ACCURATE BIOTECHNOLOGY holds a first-mover advantage in the organoid niche. The management team, led by Professor Deng Chuxia and Dr. Huang Min, demonstrates strong execution capabilities. After several years of development, the company has established comprehensive technical platforms for organoid culture, AI-based imaging quality control, and high-efficiency drug sensitivity testing. Leveraging clinical research and application data from the world’s largest organoid cohort to date, the company is building an organoid big data center, which will significantly accelerate the adoption of its organoid-related products in clinical settings and new drug development within pharmaceutical companies.”

Qudao CapitalVCBeat congratulates ACCURATE BIOTECHNOLOGY on the successful completion of its latest round of financing. As the lead investor in the previous round, Qudao Asset has continued to participate in this round to support the company’s development, demonstrating its recognition of ACCURATE BIOTECHNOLOGY’s future potential and value. We remain firmly optimistic about the broad prospects and market applications of the organoid industry, particularly its significant role in assisting patient diagnosis and treatment, accelerating preclinical R&D for pharmaceutical companies, and reducing R&D costs. As a leading enterprise in this sector, we expect ACCURATE BIOTECHNOLOGY to sustain rapid business growth, enhance its visibility in the capital markets, and deepen its influence in the healthcare field, ultimately fulfilling its corporate social responsibility and medical mission. Go, ACCURATE!